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Introduction
With advanced magnetic resonance angiography, computed tomography angiography and digital subtraction angiography (DSA), unruptured intracranial aneurysms (UIAs) are increasingly discovered in the general population, with an incidence of 3.2% in the adult population worldwide and a prevalence of 7% in a cross-sectional study from China. [1] [2] [3] [4] However, the treatment of UIAs is debatable, [5] [6] [7] [8] [9] particularly for small or very small UIAs. 10, 11 Since the publication of the International Subarachnoid Aneurysm Trial (ISAT), 12, 13 the endovascular treatment of UIAs has rapidly advanced, with a lower rate of complications, morbidity and mortality compared to that for surgical clipping. 7, 8 Furthermore, new interventional materials and technological developments, such as new flow diversion and flow disruption devices, have made endovascular treatment more durable and applicable to complex aneurysms. [14] [15] [16] [17] [18] [19] However, our main goal towards performing the endovascular treatment of UIAs was to prevent aneurysmal haemorrhage.
Headache is a symptom in approximately one-third of patients with UIAs, often leading to the diagnosis of aneurysms. 5 The severity and frequency of headache may change after an endovascular treatment. 20, 21 Some retrospective studies have reported that an endovascular treatment could relieve most preoperative headaches. [21] [22] [23] [24] [25] However, cohort studies are few, and factors related to headache relief after endovascular treatment are still not adequately evaluated. The objective of this study was to determine the effect of endovascular treatment on preoperative headache, with the primary goals of preventing aneurysmal haemorrhage and identifying factors associated with headache relief in patients with UIAs in a cohort study.
Patients and methods

Patients
The hospital ethics committee approved the study. Between January 2012 and December 2014, data of all patients with UIAs who underwent endovascular treatment were entered into a database (SPSS version 19; SPSS, Chicago, IL, USA). The database included specific information on the patient, aneurysm, symptom and treatment characteristics, such as sex, age, hypertension, concomitant diseases, aneurysm location and size, headache score, duration of headache, side of the headache to aneurysm, procedure-related complications, immediate angiographic outcomes, modalities of endovascular treatment and medications. The indication for and modality of treatment of UIAs were based on characteristics of individual patients and UIAs through interdisciplinary decision-making. The results of the International Study of Unruptured Intracranial Aneurysms (ISUIA) and Unruptured Cerebral Aneurysm Study (UCAS) of Japan served as a framework for the decision about management. 5, 9 The patients' preferences for treatment were also considered.
The patients included in our study were identified from a retrospective chart review. Figure 1 is a flow diagram of patient selection. Patients included were those with secondary headache, mainly caused by UIAs according to International Classification of Headache Disorders (ICHD) II criteria, 26 including patients with new acute headaches that resolved within 72 hours and those with recurrent undiagnosed headaches who then had new and worsening headaches that might be because of UIAs. 23 Patients with the following conditions were excluded from this study: (1) other intracranial diseases or their sequelae causing headaches, such as arteriovenous malformation, hydrocephalus, infarction, injury, haemorrhage, inflammation and brain tumours; (2) other extracranial concomitant diseases and factors that could cause or trigger headaches, such as cervical spondylosis, temporal arteritis, migraine, drugs, alcohol and exertion; 27, 28 (3) multiple intracranial aneurysms; (4) modified Rankin scale (mRS) >1; (5) patients taking analgesics at the time of headache score evaluation; and (6) parent artery occlusion alone or embolisation with Onyx (ev3, Irvine, CA, USA).
Endovascular procedures
All patients underwent endovascular treatment under general anaesthesia. A heparin bolus of 3000 IU was routinely administered as soon as a 6-F arterial sheath was placed in the common femoral artery. During the procedure, continuous heparin was used for flushing the guiding catheter system (3000 IU/500 mL of saline). A 6-F guiding catheter (Envoy; Codman Neurovascular, Miami Lakes, FL, USA) was selectively placed in the parent artery. When the optimal angiographic projection was determined, catheterisation of the aneurysm was performed by advancing a microcatheter (Echelon-10; ev3) over a microguidewire (Traxcess-14; Microvention, Aliso Viejo, CA, USA). Coils were repeatedly pushed through the microcatheter into the aneurysm until the aneurysm was embolised as densely as possible. Two types of coils were used, including Microplex (Microvention) and Axium (ev3). For wide-neck UIAs in which coiling was difficult, stents were positioned across the neck of the aneurysms before coiling, and two types of stents were used, including the Enterprise stent (Codman Neurovascular) and Solitaire stent (ev3). A balloon remodelling technique (Hyperglide or Hyperform; ev3) was also used in selective cases.
Patients with stent-assisted coiling were premedicated with dual antiplatelet therapy consisting of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 3 days. Once the stent was implanted, clopidogrel (75 mg/day) was administered for 6 weeks and aspirin (100 mg/day) was administered for 6 months.
Immediate angiographic results were evaluated by the Raymond scale (RS), 29 in which RS 1 indicates complete obliteration, RS 2 indicates near-complete obliteration, with an aneurysmal neck remnant, and RS 3 indicates incomplete obliteration, with evidence of residual filling, or large aneurysm remnant or lobule.
Evaluation of headache and headache relief
We performed a standard headache assessment on every patient before and after endovascular treatment using a quantitative 11-point headache scale (0-10), with 0 being defined as 'no headache at all' and 10 being defined as 'the worst headache you have ever experienced'. 30 The patients self-reported the headache score on the basis of this 11-point scale. Changes in headache after endovascular treatment were classified as relief (reduction in headache score), aggravation (increase in headache score) and no change. 25 The headache score was evaluated without medication for headache relief, and the patients on aspirin after endovascular treatment were evaluated after discontinuing the medication in cases of stent-assisted coiling.
Follow-up
Clinical follow-up continued with scheduled visits at 1 month, 3 months, 6 months, then annually after endovascular treatment. At least one DSA examination was performed during this period to evaluate outcomes of endovascular treatment. Headache assessment and clinical follow-up were evaluated during hospitalisation for follow-up angiogram or by telephone interview, using the headache scale and mRS (0-5). Medication information was also collected during follow-up. Morbidity was defined as mRS !2. Outcomes of imaging followup were evaluated as complete obliteration, stable remnant, progressive thrombosis in remnant and recurrence. 31 Complete obliteration was defined as 100% occlusion with no evidence of any portion of the aneurysm dome or neck filling. A stable remnant was defined as one that demonstrated no change in size from its appearance on previous imaging. Progressive thrombosis in a remnant was defined as any aneurysm with a remnant that had decreased in size on follow-up angiograms. Recurrence represented any aneurysm remnant that had increased in size or contrast filling. 31 
Statistical analysis
The data were analysed with SPSS 19.0 for Windows (SPSS Inc., Chicago, IL, USA). Patient characteristics were described by using frequencies and percentages for categorical variables, and means and standard deviations for continuous variables. Categorical variables were compared using Fisher's exact test or the Pearson 2 test. Continuous variables were compared between groups using the Mann-Whitney U-test or Student's t-test.
The primary outcome measured was headache relief. Patients reported time in months from the date of endovascular treatment until the date of headache relief or the end of follow-up (2 June 2015). Cumulative incidence of headache relief was estimated by the Kaplan-Meier product-limit method, and the resultant curves for different groups were compared using the log-rank test.
We used Cox regression analysis to calculate hazard ratio (HR) and corresponding 95% confidence interval (CI) for baseline characteristics associated with headache relief. The variables that were known at the beginning of the follow-up included: sex, age, headache score, duration of headache, side of headache to the aneurysm, aneurysm size, aneurysm location, modality of endovascular treatment, RS, hypertension and medication. We performed a univariate Cox regression analysis for all risk factors, multivariate Cox regression analysis with backward stepwise procedure (removal if P > 0.1), and Wald statistics with probability values <0.2 in univariate analysis, and adjusted for all variables as covariates in the final multivariable model. There were no missing data. The proportionality assumption was checked. A two-tailed P value < 0.05 was considered statistically significant.
Results
Baseline characteristics
Between January 2012 and December 2014, 787 patients underwent endovascular treatment for unruptured aneurysms. Of these, 624 did not meet the inclusion criteria ( Figure 1 ). Of the 123 remaining patients, the baseline characteristics grouped by later headache relief are detailed in Table 1 . Two groups differed for the side of headache to aneurysm (P < 0.001, 2 ¼ 30.020).
Other factors were not statistically significant (P > 0.05). Three patients were lost to follow-up because they changed residence (one) or telephone numbers (two). Data for these three patients were censored at the date of last follow-up. 
Incidence of headache relief
The mean follow-up duration was 14.1 AE 10.8 months (range 1-39 months). Sixty-nine patients (56.1%) had headache relief, and 54 (43.9%) had no headache relief or no change. The overall cumulative incidence of headache relief ( Figure 2 ) was 62.3% (95% CI 54.2-69.4%).
The cumulative incidence of headache relief at 12 months was 53.9% (95% CI 44.7-62.0%) and 62.3% (95% CI 49.9-69.4%) at 24 months. The log-rank test revealed that the cumulative incidence of headache relief differed with side of headache to aneurysm (P < 0.001; Figure 3 ) and aneurysm size (P ¼ 0.017, Figure 4 ).
Predictors of headache relief
In the univariate analysis, Table 2 shows that side of headache to aneurysm (inversely; HR 0.526; 95% CI 0.397, 0.697; P < 0.001) and aneurysm size (HR 1.728; 95% CI 1.072, 2.785; P ¼ 0.025), as a dichotomous variable ( 10 mm versus >10 mm), were significant predictors of headache relief.
In the multivariate analyses using backward stepwise Cox regression to search for independent predictors of headache relief among variables with probability values <0.20 in univariate analysis, side of headache to aneurysm (inversely; HR 0.536; 95% CI 0.405, 0.711; Figure 3 . The cumulative incidence of headache relief was calculated using the Kaplan-Meier method. The log-rank test reveals that the cumulative incidence of headache relief differed with side of headache to aneurysm (P < 0.001). P < 0.001) was a significant independent predictor of headache relief.
In an adjusted multivariate model with all known variables and aneurysm size as a continuous variable, HR and 95% CI did not change; however, if this was replaced by a dichotomous variable, side of headache to aneurysm (adjusted HR 0.540; 95% CI 0.408, 0.715; P < 0.001) and aneurysm size (adjusted HR 1.753; 95% CI 1.074, 2.863; P ¼ 0.025) independently predicted headache relief to a significant extent; RS (inversely; adjusted HR 0.714; 95% CI 0.480, 1.063; P ¼ 0.097) was a nearly significant predictor after adjustment for confounding factors.
Complications and outcomes of imaging and clinical follow-up
Procedure-related complications in eight patients (8/123, 6.5%) included four transient ischaemic events (4/123, 3.3%), three cerebral infarctions confirmed by CT or magnetic resonance imaging (MRI) (3/123, 2.4%), and one pseudoaneurysm (1/123, 0.8%) in the right femoral artery.
During the follow-up imaging in 105 patients (105/123, 85.4%) for a mean of 13.2 months (range 1-24 months), 75 showed complete obliteration, 18 had a stable remnant and five showed progressive thrombosis in a remnant; seven showed recurrence, for a rate of 6.7% (7/105). Of the seven recurrent patients, four were without headache relief after the first embolisation. However, after the second complete obliteration, four had headache relief during follow-up. The other three patients with recurrences were under observation.
During a clinical mean follow-up of all patients of 16.8 months (range 1-39 months), mRS 0 was seen in 69, mRS 1 in 52, mRS 2 in one and mRS 3 in one. Morbidity rate (mRS !2) was 1.6% and mortality rate was 0%.
Two patients had taken a non-steroidal antiinflammatory drug (diclofenac sodium) for 3-10 days for headaches that worsened immediately after endovascular treatment, and one had taken a non-steroidal anti-inflammatory drug (diclofenac sodium) for 8 days for a knee injury, 2 months after endovascular treatment; 97 had taken clopidogrel for 5-7 weeks and aspirin for 3-7 months after endovascular treatment; 44 had resumed preoperative antihypertensive therapy (12 took a calcium channel blocker, 20 an angiotensinconverting enzyme inhibitor, seven an angiotensin II receptor blocker, two a beta blocker, and three a calcium channel blocker combined with an angiotensinconverting enzyme inhibitor) after endovascular treatment, and two had the dosage (a calcium channel blocker) increased; seven with ischaemic complications had received symptomatic therapy for 1-3 months (including nimodipine and mecobalamin) after endovascular treatment; five had taken atorvastatin calcium because of coronary artery disease and hyperlipaemia; and two had resumed their usual preoperative treatment (one took an a-glucosidase inhibitor, and one a biguanide) for regulation of blood glucose after endovascular treatment. No other drugs, such as steroids, opioids, barbiturates, selective serotonin reuptake inhibitors, or selective noradrenalin reuptake inhibitors, were used after endovascular treatment.
Discussion
A high proportion of patients with UIAs have headaches. 5 Mechanisms by which UIAs cause headaches include local thrombosis, localised meningeal inflammation, expansion of the aneurysm, bleeding within the vascular wall, compression of the nerve and transmitted pulsation. 25, 32, 33 Endovascular treatment has become the primary treatment for UIA at our centre, and the primary goal for endovascular treatment is to prevent aneurysmal haemorrhage. However, in this study, we mainly focused on the problem of headache relief after endovascular treatment of UIAs in patients with preoperative headache. We found that endovascular coiling resulted in an overall cumulative incidence of headache relief of 62.3% in patients with preoperative headaches during a mean follow-up of 14.1 months (range 1-39 months). The cumulative incidence of headache relief was 53.9% (95% CI 44.7-62.0%) at 12 months and 62.3% (95% CI 49.9-69.4%) at 24 months. Furthermore, the Kaplan-Meier curve showed that the cumulative incidence of headache relief increased sharply in the first 12 months, but was stable after 24 months. Therefore, endovascular treatment mainly relieved preoperative headache for most patients with UIA in the first 12 months, with minimal change after 24 months.
Gu et al. 25 reported relief among 76.9% of elderly patients (!65 years) with preoperative headaches. Schwedt et al. 23 reported reduced headache frequency in 68% of patients, while 9% had new or worsened headaches following aneurysm treatment during 6 months of follow-up. Qureshi et al. 21 reported that 47.5% (19/47) had headache relief after endovascular treatment during a 9.5-year period. Kong et al. 22 reported that 89.8% had headache relief after treatment. All studies were retrospective, except for the prospective study by Schwedt et al. 23 The incidence of headache relief in the present study was lower than that of most other series. This may be attributed first to the role of medication and duration of followup. In the present study, patients who had taken aspirin and analgesics were all evaluated after stopping medication. The study by Qureshi et al. 21 had a longer follow-up time, but a lower rate of headache relief. However, other studies with a shorter follow-up time had higher rates of headache relief. The second rationale may be related to ischaemic complications such as infarction, which could cause headache. 21, 22 In the present series, seven ischaemic events (5.7%) occurred, including three cerebral infarctions (2.4%), which was higher than reported in other series. 25 The best explanation may be differences in modality of treatment; in the present series, 78.9% underwent stent-assisted coiling. Schwedt et al. 23 reported that stent-assisted coiling could be related to poorer headache outcomes due to underlying differences in aneurysm characteristics, activation of vascular sensory nerves by the stent, and remodelling of the aneurysm neck and parent artery. Finally, different standards of assessment, subgroups of patients and methods of study may influence outcomes. [21] [22] [23] [24] [25] The reasons for headache relief after endovascular treatment of UIAs could be explained by the following mechanisms. First, coil embolisation may reduce turbulence and transmitted pulsations of the aneurysm sac, 25, 32, 33 which leads to headache relief. This could account for the four recurrent patients, in whom headache probably was not relieved because of the absence of total occlusion. Second, thrombosis and fibrotic response within the embolised aneurysms may cause aneurysm retraction and decrease the mass effect at a later stage. 25 Third, the medications used at the time of treatment and hypertension control were also important factors. 23 Some patients with chronic headaches may improve after embolisation due to the anaesthesia for the procedure. Finally, some emotional factors such as anxiety and depression may increase the preoperative headache score. 23 
Predictors of headache relief
In the present study, larger UIAs caused more pain, mostly ipsilateral to the aneurysm. It is logical for a headache to be ipsilateral to the aneurysm where the aneurysm could stimulate ipsilateral afferent nerves. A UIA located at the midline could induce a bilateral headache. However, a contralateral headache may be unrelated to an aneurysm. In addition, a larger aneurysm has a larger mass effect, which may compress neighbouring tissues or nerves that could cause headaches. However, our study demonstrated that aneurysms of size >10 mm were more associated with headache relief than those of size 10 mm. Moreover, in our series, internal carotid artery aneurysms accounted for 68.3% (84/123). Therefore, our findings correlate with those of Rodrı´guez-Catarino et al. 33 that mass effect plays a minor role in cranial nerve dysfunction and headache, and that transmitted pulsations may be more important in patients with internal carotid artery aneurysms after endovascular treatment. Furthermore, transmitted pulsations from larger aneurysms may decrease more compared to those from smaller aneurysms after the endovascular treatment. Finally, the RS was a probable predictor of headache relief. Although it did not reach significance, RS 1 showed a trend indicating beneficial effects for headache relief. Complete occlusion is more beneficial for thrombosis and fibrosis in an aneurysm sac, as well as to promote endothelialisation of the neck of UIAs, which could change the haemodynamics and decrease turbulence and transmitted pulsations. Two prior reports considered the predictors of headache outcome. Gu et al. 25 reported that the preoperative headache score was associated with the outcome of headache and that a higher score predicted a lack of relief after the endovascular treatment (P ¼ 0.003). Schwedt et al. 23 reported that factors associated with a lack of headache relief included higher pretreatment trait anxiety (P ¼ 0.01), more severe pretreatment headaches (P < 0.01), stent-assisted aneurysm coiling (P ¼ 0.02) and pretreatment migraine (P ¼ 0.02). However, those studies included univariate analysis of a small number of cases with a short duration of follow-up (6 months). Results for some variables such as headache score and stent-assisted coiling in our series were not statistically significant, and should be assessed further in a larger prospective study. Other investigators aimed to identify predictors of headache outcome, but none was found. 21, 22, 24 
Strength and limitations of this study
This study is the first to analyse headache outcome after endovascular treatment of UIAs in a cohort. However, this study had several limitations. First, this was a retrospective observational study, with natural limitations. Second, it had possible case-selection bias. Our institute is a neurosurgical centre in China with a high volume of endovascular cases, and UIAs that are more complex are treated. Furthermore, it is generally difficult to diagnose secondary headaches primarily caused by UIAs because some patients may have headaches due to other causes. Third, the treatment effect may have been exaggerated due to the possible placebo effect of endovascular treatment. Finally, the number of patients in the present study was small and represented a single centre's results. Thus, the results need to be verified by a larger, multicentre prospective study during a longer follow-up period.
Conclusions
Endovascular treatment relieved preoperative headache for most patients with UIAs. Headache ipsilateral to the side of the aneurysm and aneurysm size >10 mm were significant predictors of headache relief. The correlation still needs prospective studies for validation.
